{
    "clinical_study": {
        "@rank": "26587", 
        "acronym": "GSPE", 
        "arm_group": [
            {
                "arm_group_label": "control group", 
                "arm_group_type": "Other", 
                "description": "In the control group, all patients were enrolled in a lifestyle intervention"
            }, 
            {
                "arm_group_label": "GSPE group", 
                "arm_group_type": "Active Comparator", 
                "description": "GSPE 240 mg/day (120mg bid) in addition to the same lifestyle intervention."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the antiatherogenic effect of GSPE  in clinical\n      use"
        }, 
        "brief_title": "Beneficial Effects of Grape Seed Proanthocyanidin Extrat on Progression of Atherosclerotic Plaques in Clinical Use", 
        "completion_date": {
            "#text": "October 2011", 
            "@type": "Actual"
        }, 
        "condition": "Atherosclerosis of Arteries of the Extremities, Unspecified", 
        "condition_browse": {
            "mesh_term": [
                "Atherosclerosis", 
                "Arteriosclerosis", 
                "Plaque, Atherosclerotic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Atherosclerotic plaques indicate the occurrence of ischemia events and how to deal with it\n      is a difficult task for clinical physicians. Grape seed proanthocyanidin extrat (GSPE) has\n      been reported to exert an antiatherogenic effect by inducing regression of atherosclerotic\n      plaques in animal experimental studies. In this study, the antiatherogenic effect of GSPE\n      has been investigated in clinical use."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  (1) carotid ultrasound examination: presence of carotid plaque or abnormal CIMT of\n             between 0.9 and 1.2mm; (2) lipid profile: LDL\u22663.12mmol/L, TC\u22665.2mmol/L; (3) no\n             lipid-lowering treatment within the past 6 months.\n\n        Exclusion Criteria:\n\n          -  severe cardiomyopathy, acute coronary syndrome, hepatic dysfunction, end-stage renal\n             failure (serum creatinine \u2265117mmol/L), prior carotid endarterectomy, and/or patients\n             who did not agree to participate in the present study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "43 Years"
        }, 
        "enrollment": {
            "#text": "287", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01707615", 
            "org_study_id": "2010GGC10294"
        }, 
        "intervention": [
            {
                "arm_group_label": "GSPE group", 
                "description": "GSPE 240 mg/day (120mg bid)", 
                "intervention_name": "GSPE", 
                "intervention_type": "Drug", 
                "other_name": "Grape seed proanthocyanidin extrat"
            }, 
            {
                "arm_group_label": [
                    "control group", 
                    "GSPE group"
                ], 
                "description": "dietary modification making the total ingestion of calories into standard body weight 25 kCal in effect and an individualized home exercise program of a minimum 150 min/week of moderate-intensity physical activity", 
                "intervention_name": "lifestyle intervention", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Proanthocyanidin", 
                "Procyanidin", 
                "Grape Seed Extract"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "proanthocyanidin,atherosclerosis, carotid plaque", 
        "lastchanged_date": "October 14, 2012", 
        "number_of_arms": "2", 
        "official_title": "Beneficial Effects of Grape Seed Proanthocyanidin Extrat on Progression of Carotid Intima-media Thickness and Atherosclerotic Plaques in Clinical Use", 
        "overall_official": {
            "affiliation": "Qilu Hospital", 
            "last_name": "Jie Qiu, doctor", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The common, internal, and external carotid arteries were carefully identified by combining B-mode ultrasonography and color-Doppler duplex examination in the anterior oblique, lateral, and posterior oblique planes. All data was collected in 12 segments: the near \uff08intimal-luminal surface) and far (medial- adventitial) walls of the distal common (1 cm proximal to dilation of the carotid bulb), the bifurcation (1cm proximal to the flow divider), and the proximal internal (1 cm section of the internal carotid artery immediately distal to the flow divider) left and right carotid artery.", 
            "measure": "Carotid B-Mode Ultrasound", 
            "safety_issue": "No", 
            "time_frame": "Carotid ultrasound examination was performed at baseline and 6, 12, 24months after treatment.The change of carotid plaque was record within 24 months."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01707615"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shandong University", 
            "investigator_full_name": "Jie Qiu", 
            "investigator_title": "Qilu Hospital of Shandong University", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "including hospital readmission for unstable angina, myocardial infarction, stroke, TIA, an arterial revascularization procedure (percutaneous coronary revascularization or coronary bypass surgery) and cardiac death.", 
            "measure": "clinical vascular events", 
            "safety_issue": "Yes", 
            "time_frame": "after 24 months follow-up"
        }, 
        "source": "Shandong University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Natural Science Foundation of China", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Jie Qiu", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2006", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}